Aristopharma Ltd - Affordable Healthcare in Bangladesh

Aristopharma Ltd. is one of Bangladesh's premier pharmaceutical companies, consistently ranked among the Top 10 in the industry. Built on a foundation of providing high-quality, affordable medicines, the company has grown into a major market player with a significant national and international footprint.

In the dynamic world of pharmaceuticals, where innovation meets the pressing need for accessible healthcare, Aristopharma Ltd stands tall as a beacon of quality and affordability. Established in 1986, this leading pharmaceutical company in Bangladesh has grown from humble beginnings into one of the top 10 pharmaceutical companies in Bangladesh, serving millions with a commitment to excellence. If you're searching for insights into Aristopharma Ltd's history, its diverse product portfolio, or how to contact Aristopharma Ltd, this comprehensive guide covers it all. From its robust company profile to the visionary board of directors, discover why Aristopharma is redefining healthcare delivery in South Asia and exporting to over 30 countries worldwide.

As Bangladesh's pharmaceutical sector booms—projected to reach $5 billion by 2025—Aristopharma Ltd plays a pivotal role, blending cutting-edge manufacturing with a patient-centric ethos. This article delves deep into the company's journey, offerings, and leadership, optimized for those exploring Bangladesh pharmaceutical companies or affordable medicines in Bangladesh. Let's explore the legacy of innovation and trust that defines Aristopharma.

About Aristopharma Ltd

Aristopharma Ltd isn't just a name in the pharmaceutical industry; it's a promise fulfilled. Founded with the noble vision of providing quality medicines at affordable prices, the company has become synonymous with reliable healthcare solutions for the masses. Headquartered in Dhaka, Bangladesh, Aristopharma operates two state-of-the-art manufacturing plants: one at Shampur-Kadamtali Industrial Area (just 10 km from central Dhaka) and another at Gachha, Gazipur. These facilities span over 66,000 square feet and are equipped with advanced technology compliant with global standards like UK MHRA and USFDA guidelines.

What sets Aristopharma Ltd apart in the crowded pharmaceutical market in Bangladesh? It's the unwavering focus on accessibility. In a country where healthcare costs can be prohibitive, Aristopharma ensures that life-saving drugs reach urban clinics and rural pharmacies alike. With approximately 7,000 dedicated employees, the company fosters a culture of teamwork and continuous learning. Training programs emphasize not just technical skills but also leadership and management, empowering staff to drive innovation.

Aristopharma's Research & Development (R&D) wing is the heartbeat of its creativity. Here, scientists pioneer bioequivalence studies and clinical trials for products like Omep (Omeprazole) and Afix (Cefixime), proving their efficacy matches global innovators. This commitment extends to exports: since venturing into Vietnam in 2000, Aristopharma now ships to 31 countries across five continents, including Myanmar, Sri Lanka, and African nations. In the ophthalmic segment, it's Bangladesh's undisputed leader, holding the No. 1 position since 2002.

Sustainability and corporate social responsibility (CSR) are woven into Aristopharma's fabric. Initiatives like community health camps and environmental compliance in manufacturing underscore its role as a responsible corporate citizen. For those googling top pharma companies in Bangladesh, Aristopharma's blend of tradition and modernity makes it a standout choice.

History of Aristopharma Ltd

The story of Aristopharma Ltd is one of resilience and foresight, mirroring Bangladesh's own post-independence growth. It all began in 1986, when visionary entrepreneur Md. Abul Hassan founded the company amid a nascent pharmaceutical landscape. Back then, the sector was dominated by imports, and affordable local production was a distant dream. Hassan's mission? To bridge that gap by manufacturing high-quality generics that could compete on the world stage.

The early years were marked by modest operations in a small plant at Khilgaon, Dhaka. By 1990, Aristopharma had relocated to its flagship Shampur facility, designed under Good Manufacturing Practices (GMP) standards. This move was transformative, enabling the production of a wide array of therapeutic classes: from antiulcerants and antibiotics to NSAIDs and vitamins. The 1990s saw steady expansion, with the company earning ISO 9001 certification from Orion Registrar Inc., USA—a testament to its quality journey.

A milestone arrived in 2002 when Aristopharma entered sterile ophthalmic manufacturing. This niche expertise quickly propelled it to market leadership, capturing over 20% share in Bangladesh's eye care segment. The 2010s brought high-tech innovations: expansions included inhalers, lyophilized injections, pre-filled syringes, suppositories, and biotech products like insulin. In 2017, Aristopharma boldly stepped into oncology, launching monoclonal antibodies and targeted therapies to address cancer's growing burden.

The crown jewel? The 2020s inauguration of the Gachha plant—a UK MHRA-compliant behemoth with dedicated cephalosporin lines. Ongoing constructions for ophthalmic and oncology blocks signal Aristopharma's ambition to enter regulated markets like the US and Europe. From exporting to one country in 2000 to 31 today, the history of Aristopharma Ltd reflects Bangladesh's pharmaceutical export surge, now valued at $150 million annually. Challenges like regulatory hurdles and global pandemics only fueled its adaptability, with COVID-19 prompting rapid ventilator accessory production.

Today, with 275+ brands and $359 million in revenue (as per recent estimates), Aristopharma's evolution from a local startup to a global player inspires. It's a narrative of how Bangladesh pharma history intersects with innovation, proving that quality need not be expensive.

Products of Aristopharma

At the core of Aristopharma Ltd's success is its expansive product portfolio, spanning 275 brands across 20+ therapeutic categories. Whether combating chronic diseases or everyday ailments, Aristopharma's offerings are engineered for efficacy, safety, and affordability—ideal for medicines in Bangladesh seekers.

Ophthalmic Excellence

As Bangladesh's top ophthalmic producer, Aristopharma dominates with preservative-free innovations. Standouts include:

Drylief SUD: A 1% Carboxymethylcellulose Sodium ocular lubricant in single-use drops (SUD), using US Blow-Fill-Seal technology for dry eye relief.

Systear SUD and Daily Fresh SUD: Sodium Hyaluronate 0.2% formulas for burning, irritation, and post-surgical comfort.

Optimox Eye Drops: Moxifloxacin for bacterial conjunctivitis.

Betaxol Eye Drops: Betaxolol Hydrochloride for glaucoma.

Taflan SUD: Preservative-free Tafluprost 0.015 mg for intraocular pressure reduction.

Audicare Ear Drops: Ofloxacin, Clotrimazole, Beclometasone, and Lidocaine combo for otitis externa.

These products, backed by clinical trials, ensure zero contamination risks, making Aristopharma the go-to for eye drops in Bangladesh.

Cardiovascular and Metabolic Innovations

Heart health is a priority, with cutting-edge launches like:

Sabicard Tablets (50/100/200 mg): Sacubitril & Valsartan for heart failure.

Ivabradine (Ivacaard 5/7.5 mg): Reduces heart rate in angina.

Empaglif-M: Empagliflozin + Metformin for type 2 diabetes.

Wikijet Prefilled Syringe: Tirzepatide 2.5/5 mg for glycemic control.

Duoblock: Calcium channel blocker combo for hypertension.

These align with Bangladesh's rising NCD burden, offering cardio diabetic medicines at 30-50% lower costs than imports.

Oncology and Specialized Therapies

Since 2017, Aristopharma's oncology arm has expanded rapidly:

Bevaris Injection (100/400 mg): Bevacizumab biosimilar for colorectal and lung cancers.

Rituris (100/500 mg): Rituximab for lymphoma and rheumatoid arthritis.

Arodoxin Injection (10/50 mg): Doxorubicin for breast and ovarian cancers.

Palbociclib Capsules (125 mg): CDK4/6 inhibitor for HR+ breast cancer.

Adronic (4 mg): Zoledronic Acid for bone metastases.

Supportive care includes Nipotin (Erythropoietin) for chemotherapy-induced anemia, with a dedicated helpline for patient queries.

Gastrointestinal and Anti-Infectives

For digestive woes:

Rabe (20 mg): Rabeprazole for GERD and ulcers.

Vonofix (10/20 mg): Vonoprazan for acid-related disorders.

Emep MUPS (20/40 mg): Buffered Rabeprazole for rapid onset.

Sodipic (10 mg Tablet/5 mg/5ml Solution): Sodium Picosulfate laxative.

Antibiotics shine with Afix (Cefixime), Lizox (Linezolid), and Zavicef (Ceftazidime + Avibactam) for resistant infections.

Nutritional and Women's Health

Ferijet (500 mg IV): Ferric Carboxymaltose for rapid anemia correction.

Disitol Capsules: D-chiro-inositol for PCOS management.

Neobion: B-vitamin complex for neuropathy.

Fosibon-DK: Coral calcium + Vitamins D3/K2 for osteoporosis.

Goodbac-L Syrup: Bangladesh's first probiotic syrup.

Respiratory and Pain Management

Triflo Inhalation: Triple therapy (Fluticasone + Vilanterol + Umeclidinium) for COPD.

Docopa: Doxofylline for asthma.

Joinflex-M Tablets: Collagen + Glucosamine for joint health.

Mirovan (2.5/5/10 mg): Mirogabalin for neuropathic pain.

Recent launches like Livheal (Resmetirom)—the first oral NASH/MASH therapy in Bangladesh—and Otes (Oteseconazole) for fungal infections highlight Aristopharma's innovation pipeline. All products undergo rigorous bioequivalence testing, ensuring they're as potent as branded equivalents but far more accessible. For Aristopharma products list, visit their official site for the full catalog.

Company Profile: The Pillars of Aristopharma's Success

Aristopharma Ltd's company profile reads like a blueprint for pharmaceutical excellence. Incorporated in 1986, it's a private limited entity with Md. Abul Hassan as Chairman & Managing Director. Employing 7,000+ professionals, it generates $359 million in annual turnover, focusing on generics and biosimilars.

Key pillars:

Manufacturing Prowess: Shampur plant (expanded for biotech) and Gachha (cephalosporin-dedicated, with oncology/ophthalmic builds underway).

Quality Assurance: ISO 9001:2008 certified; cGMP compliant; ongoing clinical trials at top universities.

Market Reach: 90% domestic dominance in ophthalmics; exports to 31 countries.

R&D Focus: In-house labs for formulation development, with 20+ patents pending.

Sustainability: Eco-friendly processes, CSR via health education programs.

In Bangladesh's $2.5 billion pharma market, Aristopharma's profile emphasizes ethical marketing and doctor partnerships, earning it accolades like MCCI membership.

Founded - 1986

Employees - 7,000

Plants - 2 (Dhaka & Gazipur)

Brands - 275+

Exports - 31 countries, 5 continents

Revenue (Est.) - $359M

Certifications - ISO 9001:2008, cGMP, UK MHRA

This profile positions Aristopharma as a resilient leader amid global supply chain shifts.

The Board of Directors: Visionary Leadership at the Helm

Guiding Aristopharma Ltd is a seasoned board of directors, led by the indomitable Md. Abul Hassan. As Founder, Chairman, and Managing Director, Hassan's journey from a small-scale entrepreneur to pharma titan is legendary. A pharmacist by training, he instilled the company's core philosophy: "Quality is a journey, not a goal." Under his stewardship since 1986, Aristopharma has navigated expansions, exports, and innovations, including the oncology pivot.

While detailed bios for other board members aren't publicly exhaustive, the board comprises industry veterans with expertise in finance, operations, and regulatory affairs. They oversee strategic decisions, from plant upgrades to R&D investments, ensuring alignment with global best practices. Hassan's founder's speech reflects humility: crediting his father for quality ethos and employees for execution. This collaborative board fosters a flat hierarchy, empowering mid-level leaders in marketing and production.

In a sector prone to volatility, the board's focus on diversification—e.g., biotech and exports—safeguards growth. For stakeholders eyeing Aristopharma leadership, this team embodies trust and foresight.

Contact Us: Reach Out to Aristopharma Ltd

Connecting with Aristopharma Ltd is straightforward, whether for partnerships, queries, or support.

Head Office: 7 Purana Paltan Line, Dhaka-1000, Bangladesh.

Phone: +880-2-9351691-3

Fax: +880-2-8317005

Email: info@aristopharma.com

Website: www.aristopharma.com

Specialized Helplines:

Nipotin (Erythropoietin) Support: 01997719776 (Sun-Thu, 8:30 AM–5:00 PM).

General Inquiries: Via website contact form.

For exports or media, email [email protected]. Social channels like Facebook (@aristopharmabd) offer updates. Aristopharma's responsive team ensures quick resolutions, reinforcing its patient-first approach.

Aristopharma Ltd – Building a Healthier Tomorrow

Aristopharma Ltd exemplifies how a Bangladesh pharmaceutical company can blend affordability with world-class quality. From its 1986 roots to today's global footprint, the company's history, innovative products, and visionary board of directors drive its mission forward. As it eyes regulated markets and novel therapies, Aristopharma remains committed to accessible healthcare.

Whether you're a healthcare professional, patient, or investor, exploring Aristopharma Ltd reveals a partner in wellness. For more on top pharmaceutical companies in Bangladesh, stay tuned— the future looks brighter with Aristopharma leading the way.

Aristopharma Ltd. stands as a beacon of the pharmaceutical industry in Bangladesh, embodying a 40-year commitment (since Hassan Corporation) to quality, innovation, and affordability. From its humble beginnings in 1986, the company has successfully transitioned into a global player, driven by the principle that "Quality – the unit we count" is the only path to sustainable success.

With world-class, EU GMP-approved manufacturing facilities, a deep and expanding product portfolio, and a clear vision for advancing in biotech and specialized medicine like oncology, Aristopharma is not just meeting the local healthcare needs but is also raising the profile of Bangladeshi pharmaceuticals on the international stage. Its continuous investment in R&D, clinical validation, and highly skilled personnel ensures that the company will remain a trusted partner in health for millions around the world for years to come.